Recent Updates
Recently added Catalysts
FEED Positive Sentiment

ENvue Medical Launches Over-the-Counter Reusable ENFit Syringes to Support Feeding and Medication Delivery without a Prescription

Key Takeaway: ENvue Medical has launched a line of over-the-counter ENFit Syringes aimed at improving enteral care for patients in both clinical and home settings. These syringes, available in multiple sizes, can be reused for up to seven days or 20 uses, aligning with ISO standards. The launch reflects a commitment to enhancing patient experiences and outcomes.
Price reaction · baseline $2.32 (2026-01-13 close) · hit pre-market · 1 other FEED headline(s) in the window, move may be shared
day 0 close
-26.7%
day 1
-37.1%
day 3 · peak
-47%

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of over-the-counter ENFit Syringes enhances patient access.
  • Syringes designed for reuse support sustainable practices.
  • Product meets ISO 80369-3 global standards ensuring safety.

CONCERNS & RISKS

  • Market acceptance of new products is uncertain.
  • Intense competition in the medical device industry may pose challenges.

Full Press Release Details

TYLER, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) --ENvue Medical, Inc.(NASDAQ: FEED) (NASDAQ: NAOV) (“ENvue,” “ENvue Medical” or the “Company”), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the launch of a line of over-the-counter ENFit Syringes designed to meet both feeding and medication delivery clinical needs.
“As care continues to shift beyond the hospital setting, providers and caregivers need reliable, high-quality solutions that support patients throughout the entire care journey,” said Doron Besser, MD, CEO of ENvue Medical. “With the launch of our over-the-counter ENFit Syringes, available in institutional and consumer-friendly packaging, we are expanding access to safe, affordable and standardized enteral delivery tools that support patients, caregivers, and clinicians wherever care is delivered—while remaining aligned with our mission to improve patient experiences and outcomes.”
ENvue’s ENFit Syringes are currently anticipated to be available at certain online retailers including Amazon and Durable Medical Equipment suppliers in 2.5 mL, 5 mL, 10 mL, and 60 mL sizes, without the need for a prescription. The ENFit syringes meet ISO 80369-3 global standards and are designed for reuse for up to seven days or 20 uses, helping support safe and consistent enteral delivery in both clinical and home care environments.
About ENvue Medical, Inc.ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:
Forward-Looking StatementsThis press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include, but are not limited to: statements regarding the adoption and implementation of ENvue Medical’s platforms, anticipated commercial expansion, growth, scalability, and implementation of ENvue Medical’s products, the success of ENvue’s programs, market interest in the Company’s technology, the availability of ENFit Syringes, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

Investor Contact:KCSA Strategic CommunicationsValter Pinto, Managing DirectorPH: (212) 896-1254envue@kcsa.com

Media Contact:KCSA Strategic CommunicationsRaquel Cona, Vice PresidentPH: (516) 779-2630envue@kcsa.com

Frequently Asked Questions

What are ENFit Syringes?

ENFit Syringes are over-the-counter medical devices designed for enteral feeding and medication delivery.

How long can ENFit Syringes be reused?

These syringes can be reused for up to seven days or 20 uses.

Where can I buy ENFit Syringes?

ENFit Syringes will be available at select online retailers, including Amazon.

What standards do ENFit Syringes meet?

They meet ISO 80369-3 global standards for safety and quality.

Last updated: Jan 14, 2026